{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Bortezomib will be given at a dose of 1.3 mg/m\u00b2 SC on Days 1, 8, 15, and 22 of each', '35-day cycle.', 'Dexamethasone will be given as an oral 20 mg dose on Days 1, 2, 8, 9, 15, 16, 22, 23,', '29, and 30 of each 35-day cycle.', '10.2.4.3. SVdX Patients', 'SVdX patients will return to Cycle 1 for SVd treatment (Table 8) and undergo MM evaluations', 'every 5 weeks. SVdX patients will follow the dose schedule for the SVd Arm (Section 10.2.4.1).', '10.2.4.4. SdX Patients', 'SdX patients will return to Cycle 1 for Sd treatment (Table 11) and undergo MM evaluations', 'every 5 weeks.', 'Selinexor will be given as a fixed oral 100 mg dose on Days 1, 8, 15, 22, and 29 of', 'each 35-day cycle.', 'Dexamethasone will be given as an oral 20 mg dose on Days 1, 2, 8, 9, 15, 16, 22, 23,', '29, and 30 of each 35-day cycle.', '10.2.5.', 'Selinexor Dose Escalation', 'A selinexor dose escalation may be considered for patients being treated with a', 'selinexor-containing regimen (ie, SVd Arm, SVdX treatment, or SdX treatment) who meet the', 'following 3 criteria: 1) do not achieve at least a PR within the first 2 cycles, 2) are tolerating SVd', 'well at dose level 0, and 3) do not have any AEs related to study treatment Grade >2 (National', 'Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] V. 4.03) at', 'the time of dose escalation. The dose schedule for Cycles >3 for patients who have a selinexor', 'dose escalation is provided in Table 8.', 'For Cycles >3, selinexor may be increased to a fixed oral 60 mg dose BIW during', 'Weeks 1 through 5. For patients who dose escalate, selinexor will be given as a 60 mg', 'dose on Days 1, 3, 8, 10, 15, 17, 22, 24, 29, and 31 of each 35-day cycle.', 'Dexamethasone (20 mg) will be given on the same days as selinexor.', '10.2.6.', 'Duration of Treatment and Follow-up', 'Study treatment (SVd, Vd, SVdX, or SdX) may continue until PD is confirmed by the IRC,', 'Investigator or patient decision to discontinue study treatment, pregnancy, unacceptable AEs or', 'toxicity that cannot be managed by supportive care, withdrawal of consent, death, or Sponsor', 'decision to terminate the study.', '10.3.', 'Supportive Care for All Patients', '10.3.1.', 'Required 5-HT3 Antagonists', 'In order to minimize nausea, all patients should receive 5-hydroxytryptamine (5-HT3)', 'antagonists (8 mg or equivalent) unless contraindicated, starting on C1D1 before the first dose of', 'Confidential', 'Page 61', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'study treatment and continued 2 to 3 times daily thereafter, as needed. Alternative treatment may', 'be provided if the patient does not tolerate 5-HT3 antagonists.', '10.3.2.', 'Recommended Supportive Care', 'Supportive measures for optimal medical care should be provided to all patients in both arms', 'during participation in this study. In addition to the required prophylactic therapy with 5-HT3', 'antagonists (Section 10.3.1), supportive care per institutional guidelines and/or the National', 'Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN)', 'should be used as clinically indicated at the discretion of the Investigator.', 'Supportive care guidelines for managing AEs are provided in Table 16.', '10.3.3.', 'Infection', 'No prophylactic antimicrobial agent is recommended for most patients initiating therapy with', 'selinexor. Patients with a history of recurrent infections or those at high risk for specific', 'infections may continue their prophylactic antimicrobial regimens without modification when', 'initiating selinexor therapy.', 'In patients who develop fever or other signs of systemic infection, an appropriate antimicrobial', 'should be initiated immediately. Selinexor should be suspended in any patient with a Grade 4', \"infection or sepsis (even in the absence of documented infection) until the patient's clinical\", \"condition is stabilized. Selinexor can then be restarted at the previous dose once the patient's\", 'clinical status has stabilized, even in the setting of continued IV (and/or oral) antimicrobial', 'agents. Selinexor is not known to have any drug interactions with standard antimicrobials. Please', 'also see Table 16.', '10.3.4.', 'Glucocorticoid Side Effects', 'The management of common glucocorticoid side effects is well documented. Aggressive use of', 'proton-pump inhibitors, anti-hypertensives, glucose-lowering drugs, and other agents is strongly', 'encouraged in order to maintain the use of dexamethasone in combination with selinexor in this', 'study.', 'Patients with documented osteopenia or osteoporosis should continue to take dexamethasone', 'with selinexor as indicated in the study. Standard precautions such as use of bisphosphonates', 'should be instituted unless contraindicated.', '10.3.5.', 'Overdose', 'As selinexor is metabolized by glutathione (GSH) conjugation, it is possible, but not', 'demonstrated, that hepatic GSH depletion might occur in case of extreme overdose. Therefore, in', 'patients who develop liver function test abnormalities, supportive measures such as SAM or', 'other drugs that can replace GSH might be considered as part of the overall management plan.', '10.4.', 'Dose Modifications', 'All dose modifications will be captured in the eCRF.', 'Confidential', 'Page 62', 'Version 4.0']\n\n###\n\n", "completion": "END"}